Market closed
Nuvation Bio/$NUVB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nuvation Bio
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Ticker
$NUVB
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
220
Website
Nuvation Bio Metrics
BasicAdvanced
$748M
-
-$2.11
1.47
-
Price and volume
Market cap
$748M
Beta
1.47
52-week high
$4.16
52-week low
$1.67
Average daily volume
2.5M
Financial strength
Current ratio
9.035
Quick ratio
8.911
Long term debt to equity
0.209
Total debt to equity
1.922
Interest coverage (TTM)
-491.37%
Management effectiveness
Return on assets (TTM)
-18.02%
Return on equity (TTM)
-106.27%
Valuation
Price to revenue (TTM)
75.447
Price to book
1.61
Price to tangible book (TTM)
1.63
Price to free cash flow (TTM)
-4.549
Growth
Earnings per share change (TTM)
510.16%
3-year earnings per share growth (CAGR)
68.72%
What the Analysts think about Nuvation Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Nuvation Bio stock.
Nuvation Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Nuvation Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Nuvation Bio News
AllArticlesVideos
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Business Wire·1 week ago
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
Business Wire·2 weeks ago
Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Seeking Alpha·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Nuvation Bio stock?
Nuvation Bio (NUVB) has a market cap of $748M as of March 15, 2025.
What is the P/E ratio for Nuvation Bio stock?
The price to earnings (P/E) ratio for Nuvation Bio (NUVB) stock is 0 as of March 15, 2025.
Does Nuvation Bio stock pay dividends?
No, Nuvation Bio (NUVB) stock does not pay dividends to its shareholders as of March 15, 2025.
When is the next Nuvation Bio dividend payment date?
Nuvation Bio (NUVB) stock does not pay dividends to its shareholders.
What is the beta indicator for Nuvation Bio?
Nuvation Bio (NUVB) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.